Jeryl Hilleman Biography and Net Worth

Jeryl Lynn Hilleman is a member of the Board of Directors and Audit Committee Chair of public and private companies including Novocure, a commercial international oncology company delivering a novel device therapy for solid tumors called Tumor Treating Fields (Nasdaq: NVCR) and Minerva Neurosciences (Nasdaq: NERV), a clinical stage company focused on innovative solutions for patients with central nervous system diseases. Previously, Ms. Hilleman served as a Director and Audit Committee Chair of Xenoport as well as of two non-profit organizations.

Ms. Hilleman served as a public company CFO for 20 years, raising over one billion dollars in equity and debt financings including completing 5 initial public offerings and several M&A transactions. Her experience spans biopharmaceuticals, medical devices, instrument and industrial companies. 

Ms. Hilleman participated in the Medical Sciences program at Brown University and earned an M.B.A. from the Wharton School of Business. She is a member of the 1999 class of the Henry Crown Fellows and the Aspen Global Leadership Network at the Aspen Institute and has been recognized by several annual Silicon Valley award programs for her contributions as a CFO and as a female business leader.